EuroMAbNet: European Monoclonal Antibodies Network

Members

Pierre Lafaye

Name of the laboratory

Members of the platform

Unit Leader

Pierre Lafaye plafaye@pasteur.fr

Research Engineer

Gabriel Aymé gabriel.ayme@pasteur.fr

Technicians

Gaelle Chaubeau-le Friec gaelle.chauveau-le-friec@pasteur.fr

Catherine Vivier catherine.vivier@pasteur.fr

Post-Doc

Vanina Algoçabay

PhD Student

Hiba Mejri hiba.mejri@pasteur.fr

Jean-David Randrianaly jean.randrianaly@pasteur.fr

Secretary

Hélène Ribierre mhelene.ribierre@pasteur.fr

Laboratory activity

This platform is mostly devoted to the obtaining of VHHs useful for the pasteurian community but is open to external collaborations (academic or industrial). In that respect we have developed the automation of the platform to increase the number of clones tested and to gain times in obtaining specific VHHs. However besides its service activity, the platform needs to develop research activity to explore the potentialities of VHHs to ultimately offer a better service. It is the reason we are participating as a partner or leader to several funded projects such as brain imaging of Alzheimer disease, coronabodies directed against different proteins of SARS-CoV-2, next generation of snake anti-venoms in collaboration with Pasteur network and Cryo-EM imaging with the use of VHHs directed against nicotinic receptors or bacterial pili.

Techniques available

• Obtaining VHHs from immunized alpacas
• Phage display
• Antibody characterization and conjugation
• In vivo assay

Publications (2019-present)

• Development of nanobodies as theranostic agents against CMY-2-like class C β-lactamases. Cawez F., Mercuri P.S., Morales Yanez F., Maalouf R., Vandevenne M., Kerff F., Guerin V. Mainil J.G., Thiry D., Saulmont M., Vanderplasschen A., Lafaye P., Ayme G., Bogaerts M., Dumoulin M., Galleni M. Antimicrobial Agents and Chemotherapy, 2023
• Qimeng L., Nemecz A.*, Aymé A.*, Prevost M., Pons S., Dejean de la Bâtie G., Barilone N., Baachaoui R., Maskos U., Lafaye P., Corringer P-J. Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor. bioRxiv preprint doi: https://doi.org/10.1101/2023.01.03.522562
• An original potentiating mechanism revealed by the cryoEM structures of the human a7 nicotinic receptor in complex with nanobodies. Prevost M., Barilone N., Dejean de la Bâtie G., Pons S., Aymé A., England P., Gielen M., Bontems F., Pehau-Arnaudet G., Maskos U., Lafaye P., Corringer P-J. bioRxiv preprint doi: https://doi.org/10.1101/2023.01.03.522595
• Gransagne M.*, Aymé G.*, Brier S., Chauveau-Le Friec G., Meriaux V., Nowakowski M., Dejardin F., Levallois S., Dias de Melo G, Donati F., Prot M., Brûlé S., Raynal B., Bellalou J., Goncalves P., Montagutelli X., Di SantoJ., Lazarini F., England P., Petres S., Escriou N.*, Lafaye P.* Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein . Journal of Biological Chemistry, 2022, 298(1) 101290
• Moeglin E., Desplancq D., Stoessel A., Massute C., Ranniger J., McEwen A.G., Zedze-Lutz G., Oulad-Abdelghani M., Chiper M. Lafaye P., Di Ventura B., Didier P., Poterszman A., Weiss E. A novel nanobody precisely visualizes phosphorylated histone H2AX in living cancer cells under drug-induced replication stress. Cancers, 2021, 13, 3317.
• da Costa A., Prehaud C, Bakoa F, Afonso P, Ceccaldi P-E, Lafaye P, Lafon M. A human Blood-Brain Barrier interface model to study barrier crossings by pathogens or medicines and their interaction with the brain. J. Vis. Exp. 2019, e59220

Patents

• PCT EP 2014/074066. High-affinity monoclonal anti-Strep-Tag antibody C23.21. Girard-blanc C., Krey T., Vasiliauskaite I., Nato F., Lafaye P., Dartevelle S., Rey F.
• EP 12187318.6 - 04/10/2012. New neutralizing antibodies directed against Hepatitis C virus. Krey T., Tarr A., Lafaye P., Ball J., Jestin, J-L., Rey F. EP12/187318.6 - 17/12/2012
• EP14306389.9 - PCT/EP2015/070669. Polypeptide-base carrier for the delivery of molecules across blood-brain barrier. Prehaud C, Lafaye P, Afonso P, Ceccaldi PE, Lafon M
• EP 14306388- PCT/EP2015/070669. Nanobodies suitable for neuron regeneration therapy. Prehaud C, Lafaye P, Lafon M
• PCT/FR2012/052771 – 3/11/2012. Use of anti-FcγRI and/or anti-FcγRIIA antibodies for treating arthritis ;, inflammation, thrombocytopenia and allergic shock. Jonsson F., Mancardi D., Lafaye P., Bruhns P.,
• EP 13306553.2 - 13/11/2013. Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof. Lafaye P., Bay S., Czech C., Delatour B., Dhenain M., Duyckaerts C., Grueninger F., Li T., Vandesquille M.
• EP 13306554.0 - 13/11/2013. Oligopeptides and methods for producing conjugates thereof. Lafaye P., Bay S., Czech C., Delatour B., Dhenain M., Duyckaerts C., Grueninger F., Li T., Vandesquille M.
• DI 2014-01 - EP 14152928.9 - 28/01/2014. Camelid single-domain antibodies directed against phosphorylated Tau proteins and methods for producing conjugates thereof. Lafaye P., Bay S., Czech C., Delatour B., Dhenain M., Duyckaerts C., Grueninger F., Li T., Vandesquille M.